FIELD: chemical and pharmaceutical industry.
SUBSTANCE: group of inventions relates to chemical and pharmaceutical industry, namely to a solid dosage form of Chinese lemongrass seeds and its production method. The solid dosage form of Chinese lemongrass seeds in the form of tablets with weight of 0.800±0.016 g, including active substances of Chinese lemongrass and target additives, contains as active substance ground Chinese lemongrass seeds, and as auxiliary substances microcrystalline cellulose, EMDEX, Neusilin, stevioside, sodium stearyl fumarate, sodium croscarmellose, at the following ratio, wt. %: Chinese lemongrass seeds 25.000, microcrystalline cellulose 5.000, EMDEX 58.625, Neusilin 9.000, stevioside 0.875, sodium stearyl fumarate 0.500, sodium croscarmellose 1.000. The method for the production of a solid dosage form of Chinese lemongrass seeds includes grinding of raw materials, addition of auxiliary substances, pressing of tablets, where the process of seed grinding to 0.8-1.0 mm is carried out in the presence of microcrystalline cellulose, ground Chinese lemongrass seeds with microcrystalline cellulose, as well as EMDEX, Neusilin, stevioside are placed in a mixer, dry mixing of ingredients is carried out, tablets are granulated in the presence of purified water added in sufficient amount to obtain wet mass, the resulting mass is dried to a residual moisture content of 2.0-2.5%, the resulting granulated mass is powdered with sodium stearyl fumarate and sodium croscarmellose.
EFFECT: above-described dosage form is stable during storage, is obtained without losses of fatty and ester oils in seed oil, saves technological properties – dosage of active substance, compressibility, strength, and disintegration.
2 cl, 4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION HAVING ANTI-HIV INFECTION ACTIVITY | 2017 |
|
RU2659693C1 |
MEDICINE OF SEDATIVE AND ANTISPASMODIC EFFECT AND METHOD OF PREPARATION (VERSIONS) | 2005 |
|
RU2349334C2 |
PHARMACEUTICAL COMPOSITION CONTAINING DESLORATADINE (VERSIONS) | 2013 |
|
RU2537169C1 |
CAPSULE AND DRUG PREPARATION FOR PREVENTING CARDIOVASCULAR DISEASES | 2009 |
|
RU2477123C2 |
ANTACID AND METHODS FOR PRODUCING IT (VERSIONS) | 2013 |
|
RU2567800C2 |
COMPOSITIONS CONTAINING FINELY GROUND NEBIVOLOL | 1995 |
|
RU2137473C1 |
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MENTAL, BEHAVIOUR AND COGNITIVE DISORDERS | 2012 |
|
RU2488388C1 |
PHARMACEUTICAL COMPOSITION BASED ON N-BENZYL-N-METHYL-1-PHENYLPYRROLO [1,2-A] PYRAZINE-3-CARBOXAMIDE | 2017 |
|
RU2689396C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATING CEREBROVASCULAR DISORDERS AND METHODS FOR PREPARING THEM | 2012 |
|
RU2559776C2 |
THERAPEUTICAL AGENT POSSESSING ANTIINFLAMMATORY, ANALGETIC, AND ANTIPYRETIC PROPERTIES AND A METHOD FOR PREPARATION THEREOF | 2006 |
|
RU2311179C1 |
Authors
Dates
2023-02-06—Published
2019-04-02—Filed